Evidence map›Paper›PMID 35838746›Full record

ArticleVeterinary medicine and science2022

Anti-inflammatory effect of mesenchymal stem cells on hepatocellular carcinoma in the xenograft mice model.

Saieh Hajighasemlou, Mohsen Nikbakht, Saeedreza Pakzad, Abdolnaser Azadbakht, Samad Muhammadnejad, Milad Mirmoghtadaei, Safoora Gharibzadeh, Iman Seyhoun, Javad Verdi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary medicine and science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Saieh HajighasemlouDepartment of Tissue Engineering & Applied Cell Sciences, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Mohsen NikbakhtHematology, Oncology & Stem Cell Transplantation Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Saeedreza PakzadFood and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran.
Abdolnaser AzadbakhtDepartment of Biomedical Engineering, Central Tehran Branch, Islamic Azad university, Tehran, Iran.
Samad MuhammadnejadGene Therapy Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Milad MirmoghtadaeiImmunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Safoora GharibzadehDepartment of Epidemiology and Biostatistics Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur institute, Tehran, Iran.
Iman SeyhounDepartment of Tissue Engineering & Applied Cell Sciences, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Javad VerdiDepartment of Tissue Engineering & Applied Cell Sciences, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Tehran University of Medical Sciences · IRIslamic Azad University Central Tehran Branch · IRMinistry of Health and Medical Education · IRPasteur Institute of Iran · IRStem Cell Technology Research Center · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is the fifth most diagnosed cancer and the second leading cause of cancer-related deaths worldwide. Sorafenib is the standard treatment used in the advanced stages of HCC. Cell therapy with mesenchymal stem cells (MSCs)-based cell therapy has proven effective in immune regulation and tumour growth inhibition.

objectivesIn this study, we investigated the anti-inflammatory effect of MSCs on HCC xenografts.

methodsHuman HepG2 cell lines were subcutaneously implanted into the flank of 12 nude mice, divided into three groups: the control group, the IV group (intravenous MSCs injection) and the local group (local MSCs injection). Mice were sacrificed 6 weeks after tumour implantation, and tumours were resected entirety. Quantitative real-time polymerase chain reaction (qRT-PCR) measured the gene expression of inflammatory markers, including tumour necrosis factor-α (TNF-α), interleukin (IL)-1α and IL-10. Aspartate transaminase (AST), alanine transaminase (ALT) and urea levels were measured using spectrophotometry to ensure the safety of MSC therapy.

resultsGene expressions for all three inflammatory markers were reduced in both MSCs groups compared to the control group. AST, ALT and urea levels remained in normal ranges.

conclusionsMSC therapy can reduce inflammation in HCC xenograft mouse models.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAlanine TransaminaseAnimalsAnti-Inflammatory AgentsAspartate AminotransferasesDisease Models, AnimalHeterograftsHumansInterleukin-10MiceMice, NudeSorafenibTumor Necrosis Factor-alphaAlanine TransaminaseAnti-Inflammatory AgentsAspartate AminotransferasesInterleukin-10SorafenibTumor Necrosis Factor-alphahepatocellular carcinomahuman placentainflammationmesenchymal stem cells

Identifiers

PMID35838746
PMCPMC9514506
OpenAlexW4285492616

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.